In this new update, patients are divided into three molecular groups: CIMP negative, CIMP positive 1p/19q codeleted, and CIMP positive 1p/19q non-codeleleted. CIMP positivity in this study is essentially another way of saying "IDH-mutant" as IDH mutation virtually always leads to the CpG Island Methylator Phenotype (CIMP). The latter two subgroups correspond to molecular oligodendroglioma and molecular astrocytoma, respectively.
One of the more important findings in this study is that PCV was superior to TMZ in the molecular oligodendroglioma subgroup. (This image shows progression-free survival, but the same trend was evident in time-to-treatment failure analysis and overall survival).
This study was published in the November 2016 edition of Neuro-Oncology, and the figures above are taken from the Supplementary figures.